CC-92480: A Promising CELMoD with Potent Anti-Myeloma and Immune-Stimulating Properties

CC-92480 is a new drug being tested in a clinical trial for patients with relapsed or resistant multiple myeloma (RRMM). This drug is a cereblon E3 ligase modulator that can change how certain proteins work in the body. It has shown to be very effective in reducing the amount of two proteins, Ikaros and Aiolos, which are important for the survival of myeloma cells. CC-92480 binds to cereblon with a much higher affinity than other drugs like lenalidomide and pomalidomide, leading to better destruction of Ikaros and Aiolos.

This drug also works well on many different types of myeloma cells, including those that have become resistant to other treatments. It can cause these cells to stop growing and to die, which is especially important for cells that are not affected by current treatments. In addition to this, CC-92480 can activate immune cells and increase the production of certain proteins that help the immune system fight cancer.

The study found that CC-92480 is able to cause the death of myeloma cells in a way that depends on cereblon, and it can also help the immune system to kill these cells. The results of this study suggest that CC-92480 could be a promising new treatment for patients with RRMM.

Several authors of the study have affiliations with pharmaceutical companies, including Celgene Corporation and Global Blood Therapeutics (GBT), where they hold positions such as employment and equity ownership.